SCHEMBL3255477

SCHEMBL3255477

S=C1N[C@H](c2cccc(Cl)c2)[C@H](c2cccc(Cl)c2)N1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
MCL1 Q07820 1/20 0.46
MAPT P10636 2/20 0.42
ALDH1A1 P00352 2/20 0.42
HPGD P15428 2/20 0.42
GAA P10253 1/20 0.42
TSHR P16473 1/20 0.42
TP53 P04637 1/20 0.42
MDM2 Q00987 1/20 0.42
SLC6A3 Q01959 5/20 0.40
SLC6A2 P23975 3/20 0.40
HTR2A P28223 2/20 0.40
HTR2C P28335 2/20 0.40
HTR2B P41595 2/20 0.40
KDM4E B2RXH2 1/20 0.37
LMNA P02545 1/20 0.37
GID4 Q8IVV7 1/20 0.37
P2RX7 Q99572 1/20 0.37
TAAR1 Q96RJ0 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3255478 1.00 MEN1 (0.46) MEN1KMT2AMCL1MAPTALDH1A1
SCHEMBL3259563 0.76 KMT2A (0.51) MEN1KMT2AMAPTALDH1A1HPGD
SCHEMBL3255381 0.76 P2RX7 (0.53) MAPTALDH1A1HTR2AHTR2CHTR2B
SCHEMBL3259567 0.76 KMT2A (0.51) MEN1KMT2AMAPTALDH1A1HPGD
SCHEMBL3255375 0.76 P2RX7 (0.53) MAPTALDH1A1HTR2AHTR2CHTR2B
SCHEMBL3256203 0.74 HTR3A (0.41) MEN1KMT2AMAPTALDH1A1HPGD
SCHEMBL3256205 0.74 HTR3A (0.41) MEN1KMT2AMAPTALDH1A1HPGD
SCHEMBL3259222 0.73 MEN1 (0.47) MEN1KMT2AMAPTALDH1A1HPGD
SCHEMBL3258947 0.73 MEN1 (0.47) MEN1KMT2AMAPTALDH1A1HPGD
SCHEMBL3257578 0.73 MEN1 (0.47) MEN1KMT2AMAPTALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7741493-B2 4,5-diphenyl-2-amino-4,5-dihydro-imidazole derivatives; antiinflammatory agent, neurodegenerative diseases; inflammatory bowel disease, rheumatoid arthritis and diseases associated with central nervous system, such as Alzheimer's disease AVENTIS PHARMACEUTICALS INC. (US) 2010-06-22 US disclosed
EP-1651613-B1 4,5-DIHYDRO-IMIDAZOLE AS P2X7 ION CHANNEL BLOCKERS AVENTIS PHARMA INC (US) 2010-05-26 EP disclosed
US-20080132550-A1 HETEROCYCLIC COMPOUNDS AS P2X7 ION CHANNEL BLOCKERS AVENTIS PHARMACEUTICALS INC. (US) 2008-06-05 US disclosed
US-7326792-B2 Heterocyclic compounds as P2X7 ion channel blockers AVENTIS PHARMACEUTICALS INC. (US) 2008-02-05 US disclosed
EP-1651613-A1 4,5-DIHYDRO-IMIDAZOLE AS P2X7 ION CHANNEL BLOCKERS Aventis Pharmaceuticals, Inc. (US) 2006-05-03 EP disclosed
WO-2005014555-A1 4,5-DIHYDRO-IMIDAZOLE AS P2X7 ION CHANNEL BLOCKERS AVENTIS PHARMACEUTICALS INC. (US) 2005-02-17 WO disclosed
US-20050026916-A1 Heterocyclic compounds as P2X7 ion channel blockers AVENTIS PHARMACEUTICALS INC. (US) 2005-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080132550-A1 HETEROCYCLIC COMPOUNDS AS P2X7 ION CHANNEL BLOCKERS P2RX3, P2RX2, P2RX5 MEN1 3313/4885KMT2A 3229/4885MCL1 3435/4885
US-20050026916-A1 Heterocyclic compounds as P2X7 ion channel blockers P2RX3, P2RX2, P2RX5 MEN1 3313/4885KMT2A 3229/4885MCL1 3435/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.